A single subcutaneous dose led to a 4-point or greater itch reduction in 82% of patients with chronic pruritus at week 12 vs 22% with placebo, Attovia reported.
At a Dermatology Times Case-Based Roundtable event moderated by Gaurav Singh, MD, MPH, clinicians discussed whether 40-GEP results change radiation, imaging, and follow-up in high-risk cutaneous squamous cell carcinoma.